CTOs on the Move

Scribe Therapeutics

www.scribetx.com

 
Scribe is focused on the engineering, delivery, and development of next-generation CRISPR molecules to rewrite and repair the underlying cause of genetic disorders.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.scribetx.com
  • 1150 Marina Village Pkwy
    Alameda, CA USA 94501
  • Phone: 908.642.7374

Executives

Name Title Contact Details

Similar Companies

Osel Inc

Osel Inc is a Mountain View, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Mascoma Corporation

Mascoma Corporation is a Brighton, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Spring Bank Pharmaceuticals

Spring Bank Pharmaceuticals (NASDAQ: SBPH) is a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using our proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. SMNH compounds are small segments of nucleic acids that the company designs to selectively target and modulate the activity of specific proteins implicated in various disease states. Spring Bank is developing its most advanced SMNH product candidate, inarigivir soproxil (formerly referred to as SB 9200), for the treatment of viral diseases, including hepatitis B virus (HBV), and other SMNH product candidates, including SB 11285, the company`s lead immunotherapeutic agent for the treatment of selected cancers through the activation of the STimulator of Interferon Genes, or STING, pathway.

Molecular Pharmacology Limited (USA)

Molecular Pharmacology Limited (USA) is a West Hollywood, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Aldeyra Therapeutics, Inc

Aldeyra Therapeutics, Inc., is a biotechnology company focused primarily on the development of products to treat diseases thought to be related to endogenous free aldehydes, a naturally occurring class of toxic molecules. The company has developed NS2, a product candidate designed to trap free aldehydes. Aldeyra plans to begin clinical testing of NS2 in 2014 for the treatment of Sjögren-Larsson Syndrome and acute anterior uveitis. NS2 has not been approved for sale in the U.S. or elsewhere.